KCM
ITCI

Kennedy Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Kennedy Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,822
Closed -$768K – 690
2025
Q1 		$768K Buy
5,822
+75
+1% +$9.35K 0.02% 549
2024
Q4 		$480K Buy
5,747
+1,065
+23% +$87.5K 0.01% 636
2024
Q3 		$343K Buy
4,682
+1,108
+31% +$83.3K 0.01% 649
2024
Q2 		$245K Sell
3,574
-15,747
-82% -$1.09M 0.01% 673
2024
Q1 		$1.34M Sell
19,321
-8,046
-29% -$553K 0.03% 591
2023
Q4 		$1.96M Sell
27,367
-2,450
-8% -$141K 0.04% 496
2023
Q3 		$1.55M Sell
29,817
-39,917
-57% -$2.33M 0.04% 505
2023
Q2 		$4.42M Sell
69,734
-38,620
-36% -$2.41M 0.1% 318
2023
Q1 		$5.87M Sell
108,354
-200,292
-65% -$9.68M 0.17% 222
2022
Q4 		$16.3M Sell
308,646
-14,963
-5% -$750K 0.46% 37
2022
Q3 		$15.1M Buy
323,609
+70,290
+28% +$3.67M 0.44% 45
2022
Q2 		$14.5M Buy
253,319
+12,064
+5% +$684K 0.41% 55
2022
Q1 		$14.8M Buy
241,255
+36,433
+18% +$1.89M 0.35% 74
2021
Q4 		$10.7M Buy
204,822
+106,466
+108% +$4.47M 0.23% 155
2021
Q3 		$3.67M Buy
+98,356
New +$3.42M 0.08% 400

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kennedy Capital Management's ITCI Position: Q2 2025 in Review

Kennedy Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,822 shares — an estimated $768K sold.

Kennedy Capital Management first reported a position in ITCI in Q3 2021 and held it in 15 quarters. The position peaked at $16.3M in Q4 2022. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Kennedy Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 5,822 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $768K.
  • Kennedy Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2021 and held it in 15 quarters.
  • Kennedy Capital Management's Intra-Cellular Therapies Inc. position peaked at $16.3M in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Kennedy Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.